Supplementary Figure S6 from Phase I study of SYNB1891, an engineered E coli Nissle strain expressing STING agonist, with and without atezolizumab in advanced malignancies
Year: 2024
Type: supplementary-materials
Abstract: Supplemental Figure 6. Tumor biopsy gene expression changes in antigen presenting pathways after SYNB1891 treatment.
Language: English
Topic: Bacterial Cancer Therapy
Subfield: Biotechnology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4402803376
Cites:
Cited by:
Related to: